- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arrowhead Pharmaceuticals Inc (ARWR)
Arrowhead Pharmaceuticals Inc stock price live, this page displays NASDAQ ARWR stock exchange data. View the ARWR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Arrowhead Pharmaceuticals Inc real time stock price chart below.
What Is the Arrowhead Pharmaceuticals Inc Stock Price Today?
The Arrowhead Pharmaceuticals Inc stock price today is 67.05.
What Is the Stock Symbol for Arrowhead Pharmaceuticals Inc?
The stock symbol for Arrowhead Pharmaceuticals Inc is "ARWR."
What Stock Exchange Does Arrowhead Pharmaceuticals Inc Trade On?
Arrowhead Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Arrowhead Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Arrowhead Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARWR quote. (ISIN: US04280A1007)
What Is the Arrowhead Pharmaceuticals Inc Stock Price Today?
The Arrowhead Pharmaceuticals Inc stock price today is 67.05.
What Is the Stock Symbol for Arrowhead Pharmaceuticals Inc?
The stock symbol for Arrowhead Pharmaceuticals Inc is "ARWR."
What Stock Exchange Does Arrowhead Pharmaceuticals Inc Trade On?
Arrowhead Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Arrowhead Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Arrowhead Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARWR quote. (ISIN: US04280A1007)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
66.85
71.16
52 wk Range
9.57
76.76
Earnings results expected in 10 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
66.8571.16
52 wk Range
9.5776.76
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ARWR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
81.92
Upside
+22.17%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Arrowhead Pharmaceuticals Inc Company Profile
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals Inc SWOT Analysis
Plozasiran's Promise | Arrowhead's lead drug candidate for FCS treatment nears potential FDA approval, showcasing strong Phase 3 results and advantages over competitors |
Strategic Pivot | Explore Arrowhead's shift towards cardio-metabolic treatments, allocating 75% of R&D spending to this promising area |
Market Valuation | Despite pipeline progress, stock underperforms biotech index. Analysts view current price as attractive, with targets ranging from $42 to $73 |
Future Horizons | Delve into Arrowhead's innovative integrin-targeting approach, potentially expanding applications in muscle-related disorders and differentiating from competitors |
Arrowhead Pharmaceuticals Inc Earnings Call Summary for Q4/2025
- Arrowhead reported Q4 2025 with $829M revenue from licensing deals, a net loss of $2M ($0.01/share), and stock rose 5.69% to $44.26 following FDA approval of Redemplo for FCS.
- The company has transitioned to commercial stage with Redemplo approval, maintaining $919M in cash/investments as of September 30, with runway extended into fiscal 2028.
- Arrowhead expects a $200M milestone payment from Sarepta in January 2026 and is preparing for data readouts on obesity treatments and pediatric studies for Redemplo.
- CEO Chris Anzalone emphasized the company's pipeline diversity and ambition to become a large, profitable biotech firm while maintaining rational drug pricing strategies.
- Management plans for potential Redemplo label expansion with an SNDA filing by 2026, while addressing challenges including pancreatitis risk and market adoption.
Last Updated: 2025-11-25, 05:56 p/m
Read Full TranscriptCompare ARWR to Peers and Sector
Metrics to compare | ARWR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARWRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5,649.7x | −1.6x | −0.6x | |
PEG Ratio | −56.64 | 0.09 | 0.00 | |
Price/Book | 19.8x | 4.0x | 2.6x | |
Price / LTM Sales | 11.1x | 9.7x | 3.4x | |
Upside (Analyst Target) | 23.0% | 53.4% | 41.8% | |
Fair Value Upside | Unlock | 7.6% | 4.8% | Unlock |
Analyst Ratings
9 Buy
4 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 81.92
(+22.17% Upside)
Earnings
Latest Release
Nov 25, 2025
EPS / Forecast
-0.11 / -0.3099
Revenue / Forecast
256.47M / 164.04M
People Also Watch
FAQ
What Is the Arrowhead Pharma (ARWR) Stock Price Today?
The Arrowhead Pharma stock price today is 67.05
What Stock Exchange Does Arrowhead Pharma Trade On?
Arrowhead Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Arrowhead Pharma?
The stock symbol for Arrowhead Pharma is "ARWR."
What Is the Arrowhead Pharma Market Cap?
As of today, Arrowhead Pharma market cap is 9.21B.
What Is Arrowhead Pharma's Earnings Per Share (TTM)?
The Arrowhead Pharma EPS (TTM) is -0.01.
When Is the Next Arrowhead Pharma Earnings Date?
Arrowhead Pharma will release its next earnings report on Feb 05, 2026.
From a Technical Analysis Perspective, Is ARWR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Arrowhead Pharma Stock Split?
Arrowhead Pharma has split 2 times.
How Many Employees Does Arrowhead Pharma Have?
Arrowhead Pharma has 711 employees.
What is the current trading status of Arrowhead Pharma (ARWR)?
As of Jan 26, 2026, Arrowhead Pharma (ARWR) is trading at a price of 67.05, with a previous close of 67.05. The stock has fluctuated within a day range of 66.85 to 71.16, while its 52-week range spans from 9.57 to 76.76.
What Is Arrowhead Pharma (ARWR) Price Target According to Analysts?
The average 12-month price target for Arrowhead Pharma is USD81.92, with a high estimate of USD110 and a low estimate of USD35. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +22.17% Upside potential.
What Is the ARWR Premarket Price?
ARWR's last pre-market stock price is 66.28. The pre-market share volume is 4,350.00, and the stock has decreased by -0.77, or -1.15%.
What Is the ARWR After Hours Price?
ARWR's last after hours stock price is 66.09, the stock has decreased by -0.96, or -1.43%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.